CIBC Asset Management
KYMR icon

CIBC Asset Management’s Kymera Therapeutics KYMR Stock Holding History

CIBC Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$289K Sell
2,524
-415
-14% -$35.7K ﹤0.01% 1074
2026
Q1 		$245K Hold
2,939
– – ﹤0.01% 1107
2025
Q4 		$229K Buy
+2,939
New +$198K ﹤0.01% 1137

Other funds holding KYMR

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

CIBC Asset Management's KYMR Position: Q2 2026 in Review

CIBC Asset Management reduced its Kymera Therapeutics (KYMR) stake by 14% in Q2 2026, selling an estimated $35.7K and leaving 2,524 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #1074.

CIBC Asset Management first reported a position in KYMR in Q4 2025 and has held it in 3 quarters since. 67 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • CIBC Asset Management held 2,524 shares of Kymera Therapeutics worth $289K as of Q2 2026.
  • CIBC Asset Management sold 415 Kymera Therapeutics shares in Q2 2026, an estimated $35.7K.
  • Kymera Therapeutics made up ﹤0.01% of CIBC Asset Management's portfolio in Q2 2026, its #1074 holding.
  • CIBC Asset Management first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 67 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.